Table 4. Single-haplotype analysis of decrease in systolic BP and norepinephrine plasma concentrations (NE) after dexmedetomidine.

Decrease of systolic BP and NE was assessed as difference between the area under the curve for the respective variables between placebo infusions and dexmedetomidine infusions (ΔAUC_SBP and ΔAUC_NE, respectively). Uncorrected p-values are from multiple linear regression analysis assuming an additive model of inheritance. Adjusted p-values are after adjustment for the covariates AUC_SBP or AUC_NE during placebo, respectively, dexmedetomidine plasma concentrations, age, sex, race, and BMI. Except placebo AUC_SBP and placebo AUC_NE, respectively (P<0.021 in all analyses), no other covariate was significantly associated with the outcomes.

	ΔAUCSBP, mmHg* hr (mean±SD)					ΔAUCNE, pg/mL* hr (mean±SD)
Haplotype	Number of haplotype copies			P-value	Adjusted P-value	Number of haplotype copies			P-value	Adjusted P-value
	0	1	2			0	1	2
HT1	−12.1±7.7 n=23	−11.5±6.2 n=25	−9.5±5.0 n=23	0.17	0.77	−107.8±74.7 n=23	−77.6±65.7 n=24	−119.2±80.2 n=23	0.60	0.46
HT2	−10.6±6.4 n=65	−15.3±5.5 n=6	n.a. n=0	0.09	0.18	−99.6±76.6 n=65	−118.2±52.8 n=6	n.a. n=0	0.56	0.52
HT3	−11.6±6.2 n=63	−6.1±7.2 n=7	−9.5 n=1	0.034*	0.008*	−101.2±71.8 n=63	−73.9±70.6 n=7	−291.3 n=1	0.99*	0.81*
HT4	−10.1±5.8 n=51	−12.1±5.8 n=19	−22.8±7.4 n=3	0.002	0.028	−104.6±77.1 n=50	−88.6±69.7 n=19	−69.3±111.4 n=3	0.44	0.18
HT5	−11.2±6.6 n=40	−10.8±6.4 n=28	−10.8±4.9 n=3	0.79	0.16	−110.6±79.0 n=40	−89.6±71.5 n=27	−79.3±19.7 n=3	0.49	0.35

^*For statistical analysis, the single subject homozygous for HT3 was grouped with the 7 heterozygous carriers.

HT=haplotype, n.a.= not represented in cohort.